pharmaphorum January 8, 2026
In its second AI-focused deal in the space of a week, Servier has announced a partnership with Iktos aimed at finding new, small-molecule therapies for a range of diseases, including cancer and neurological conditions.
The alliance with Paris, France-based Iktos could be worth more than €1 billion in upfront, research funding, and milestone payments, according to the two companies, and covers multiple targets.
Under the terms of the deal, Iktos will use its generative AI and AI-orchestrated robotics platform to come up with candidates that Servier will then take forward into preclinical and clinical development.
It’s the latest in a series of collaborations by Servier to build up its pipeline, and comes just a few days after it forged a...
Today's Sponsors
Today's Sponsor